Article
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
British journal of cancer - 11 Jul 2017
Alvi Muhammad A, Loughrey Maurice B, Dunne Philip, McQuaid Stephen, Turkington Richard, Fuchs Marc-Aurel, McGready Claire, Bingham Victoria, Pang Brendan, Moore Wendy, Maxwell Perry, Lawler Mark, James Jacqueline A, Murray Graeme I, Wilson Richard H, Salto-Tellez Manuel
Abstract excerpt
BACKGROUND: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease. METHODS: Using test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
